FN3K and cancer: Substantial studies are required to examine the activity of Nrf2 inhibitors/semisynthetic camptothecin derivatives like irinotecan, and topotecan along with FN3K inhibitors (oxaliplatin) in combinatorial regimens to target several cancers.